KR100884500B1 - 수베로일아닐리드 하이드록삼산의 제형 및 이의 제조방법 - Google Patents

수베로일아닐리드 하이드록삼산의 제형 및 이의 제조방법 Download PDF

Info

Publication number
KR100884500B1
KR100884500B1 KR1020077003998A KR20077003998A KR100884500B1 KR 100884500 B1 KR100884500 B1 KR 100884500B1 KR 1020077003998 A KR1020077003998 A KR 1020077003998A KR 20077003998 A KR20077003998 A KR 20077003998A KR 100884500 B1 KR100884500 B1 KR 100884500B1
Authority
KR
South Korea
Prior art keywords
active ingredient
delete delete
crystalline
particle size
saha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077003998A
Other languages
English (en)
Korean (ko)
Other versions
KR20070062505A (ko
Inventor
지아니 차우 웡
아론 에스 코테
에릭 에이 디네만
킴벌리 갤러허
크레이그 이케다
져스틴 모세르
파볼 라즈니아크
로버트 에이 리드
신디 스타벅
시엔-신 퉁
칭시 왕
벤자민 맥스 코헨
빈센트 알 카포다노
브라이언 셀
토마스 에이 밀러
Original Assignee
머크 앤드 캄파니 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100884500(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 머크 앤드 캄파니 인코포레이티드 filed Critical 머크 앤드 캄파니 인코포레이티드
Publication of KR20070062505A publication Critical patent/KR20070062505A/ko
Application granted granted Critical
Publication of KR100884500B1 publication Critical patent/KR100884500B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020077003998A 2005-05-20 2006-05-16 수베로일아닐리드 하이드록삼산의 제형 및 이의 제조방법 Expired - Fee Related KR100884500B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68287505P 2005-05-20 2005-05-20
US60/682,875 2005-05-20
US69312805P 2005-06-23 2005-06-23
US60/693,128 2005-06-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020087030074A Division KR100993135B1 (ko) 2005-05-20 2006-05-16 수베로일아닐리드 하이드록삼산의 제형 및 이의 제조방법

Publications (2)

Publication Number Publication Date
KR20070062505A KR20070062505A (ko) 2007-06-15
KR100884500B1 true KR100884500B1 (ko) 2009-02-20

Family

ID=37452585

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087030074A Expired - Fee Related KR100993135B1 (ko) 2005-05-20 2006-05-16 수베로일아닐리드 하이드록삼산의 제형 및 이의 제조방법
KR1020077003998A Expired - Fee Related KR100884500B1 (ko) 2005-05-20 2006-05-16 수베로일아닐리드 하이드록삼산의 제형 및 이의 제조방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020087030074A Expired - Fee Related KR100993135B1 (ko) 2005-05-20 2006-05-16 수베로일아닐리드 하이드록삼산의 제형 및 이의 제조방법

Country Status (20)

Country Link
US (4) US8093295B2 (enExample)
EP (2) EP1853245A2 (enExample)
JP (2) JP5264174B2 (enExample)
KR (2) KR100993135B1 (enExample)
AR (1) AR055953A1 (enExample)
AU (3) AU2006249440C1 (enExample)
BR (1) BRPI0605893A (enExample)
CA (1) CA2580367C (enExample)
CR (1) CR8912A (enExample)
DO (1) DOP2006000113A (enExample)
EC (1) ECSP077263A (enExample)
IL (1) IL181070A0 (enExample)
MA (1) MA28804B1 (enExample)
MX (1) MX2007002047A (enExample)
MY (1) MY144613A (enExample)
NI (1) NI200700031A (enExample)
NZ (2) NZ553204A (enExample)
PE (1) PE20061390A1 (enExample)
TW (2) TWI415603B (enExample)
WO (2) WO2006127319A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
NZ592686A (en) 2008-10-15 2012-12-21 Generics Uk Ltd Process for the preparation of vorinostat from aniline, hydroxylamine and suberic acid starting materials
JP2012509929A (ja) * 2008-11-26 2012-04-26 ジェネリクス・（ユーケー）・リミテッド 多型
US20110269838A1 (en) * 2008-11-26 2011-11-03 Vinayak Gore Novel processes and pure polymorphs
US20110313044A1 (en) * 2010-06-18 2011-12-22 Urquima S.A. Polymorphs of Suberoylanilide Hydroxamic Acid
US11060092B2 (en) 2016-07-13 2021-07-13 Technion Research & Development Foundation Limited Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
AU2020326612B2 (en) 2019-08-02 2025-10-23 Onehealthcompany, Inc. Treatment of canine cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075839A2 (en) * 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
US20040122101A1 (en) * 2002-03-04 2004-06-24 Miller Thomas A. Polymorphs of suberoylanilide hydroxamic acid

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5608108A (en) 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
WO2000021979A2 (en) 1998-10-13 2000-04-20 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide and their use as histone deacetylase inhibitor
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
HUP0202707A3 (en) 1999-09-08 2003-11-28 Univ Columbia Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and pharmaceutical compositions containing them and use thereof
WO2001038322A1 (en) 1999-11-23 2001-05-31 Methylgene, Inc. Inhibitors of histone deacetylase
US7288567B2 (en) 2000-03-24 2007-10-30 Methylgene Inc. Inhibitors of histone deacetylase
WO2002015921A2 (en) 2000-08-18 2002-02-28 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6888027B2 (en) 2000-09-29 2005-05-03 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1532244A4 (en) 2001-06-14 2005-12-14 Bristol Myers Squibb Co NEW HISTONIC HUMAN DEACETYLASES
AU2002340253C1 (en) 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US20040132643A1 (en) 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
AU2003219803B8 (en) 2002-02-15 2005-08-25 Sloan-Kettering Institute For Cancer Research Method of treating TRX mediated diseases
US20070060614A1 (en) 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040132825A1 (en) 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20060276547A1 (en) 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
AU2003226408B2 (en) 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
WO2004046104A2 (en) 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
AU2004228011A1 (en) 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
PL379887A1 (pl) * 2003-08-26 2006-11-27 Merck Hdac Research, Llc Sposób leczenia raka inhibitorami HDAC
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
JP2009504774A (ja) 2005-08-18 2009-02-05 メルク エンド カムパニー インコーポレーテッド 癌を治療するためにｓａｈａ及びターグレチンの併用方法
CN101300015A (zh) 2005-11-04 2008-11-05 默克公司 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法
EP1942884A4 (en) 2005-11-04 2010-01-06 Merck & Co Inc METHOD FOR THE TREATMENT OF CANCER WITH SAHA, CARBOPLATIN AND PACLITAXEL AND OTHER COMBINATION THERAPIES
US20070197473A1 (en) 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075839A2 (en) * 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
US20040122101A1 (en) * 2002-03-04 2004-06-24 Miller Thomas A. Polymorphs of suberoylanilide hydroxamic acid

Also Published As

Publication number Publication date
WO2006127319A3 (en) 2007-03-29
WO2006127319A2 (en) 2006-11-30
US20100113829A1 (en) 2010-05-06
AU2009201652A1 (en) 2009-05-21
AR055953A1 (es) 2007-09-12
JP5308486B2 (ja) 2013-10-09
NI200700031A (es) 2008-03-03
US8450372B2 (en) 2013-05-28
AU2009201650B2 (en) 2011-09-15
JP5264174B2 (ja) 2013-08-14
TWI415603B (zh) 2013-11-21
JP2008519081A (ja) 2008-06-05
EP2292221A2 (en) 2011-03-09
EP2292221A3 (en) 2011-08-10
DOP2006000113A (es) 2006-10-31
AU2006249440C1 (en) 2009-08-13
KR100993135B1 (ko) 2010-11-10
CA2580367A1 (en) 2006-11-30
CR8912A (es) 2008-02-21
WO2006127321A3 (en) 2007-03-22
JP2011251985A (ja) 2011-12-15
EP1853245A2 (en) 2007-11-14
WO2006127321A2 (en) 2006-11-30
MY144613A (en) 2011-10-04
US20100119596A1 (en) 2010-05-13
AU2009201650A1 (en) 2009-05-21
NZ594669A (en) 2013-02-22
AU2010201359A1 (en) 2010-04-29
CA2580367C (en) 2012-08-21
MA28804B1 (fr) 2007-08-01
TW201034660A (en) 2010-10-01
US20080132575A1 (en) 2008-06-05
PE20061390A1 (es) 2007-01-15
US8093295B2 (en) 2012-01-10
MX2007002047A (es) 2007-04-12
TW200727892A (en) 2007-08-01
NZ553204A (en) 2011-09-30
AU2006249440A1 (en) 2006-11-30
ECSP077263A (enExample) 2007-04-26
US20100112046A1 (en) 2010-05-06
AU2009201652B2 (en) 2011-10-06
AU2006249440B2 (en) 2009-03-12
US8288440B2 (en) 2012-10-16
IL181070A0 (en) 2007-07-04
TWI365068B (en) 2012-06-01
KR20070062505A (ko) 2007-06-15
BRPI0605893A (pt) 2007-12-18
KR20080113135A (ko) 2008-12-26

Similar Documents

Publication Publication Date Title
JP5308486B2 (ja) スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法
KR20090064400A (ko) Ｈｄａｃ 억제제 및 킬레이트화 가능한 금속 화합물 및 금속-ｈｄａｃ 억제제 킬레이트 착물의 약제학적 조성물
CN101080223B (zh) 辛二酰苯胺异羟肟酸制剂及其制备方法
US20100035991A1 (en) Amide base salts of saha and polymorphis thereof
CN120731200A (zh) 作为ras抑制剂的3-ah环戊二烯并[b]苯并呋喃-3a-基化合物
WO2024035830A1 (en) Solid forms of a cdk inhibitor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 7, Claim Number : 15, 20, 21, 23, 25, 35 38, Period Limitation Text : 81, Comment Text : 144

St.27 status event code: A-4-4-G10-G18-tex-PA0101

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20121017

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PE0702 Decision to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 7, Claim Number : 15, 20, 21, 23, 25, 35 38, Period Limitation Text : 81, Comment Text : 144

St.27 status event code: A-4-4-G10-G20-tex-PE0702

FPAY Annual fee payment

Payment date: 20140129

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20150129

Year of fee payment: 7

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 8

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 9

PR1001 Payment of annual fee

Fee payment year number: 9

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20171228

Year of fee payment: 10

PR1001 Payment of annual fee

Fee payment year number: 10

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 11

PR1001 Payment of annual fee

Fee payment year number: 11

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 12

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 13

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 14

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

Fee payment year number: 15

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20240213

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240213

St.27 status event code: N-4-6-H10-H13-oth-PC1903